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The prion protein (PrP) is crucially involved in transmissible spongiform encephalopathies (TSE), but neither its exact role in
disease nor its physiological function are known. Here we show for mice, using histological, immunochemical and PCR-based
methods,thatstimulationofinnateresistancewasfollowedbyappearanceofnumerousendogenousretrovirusesandensuingPrP
up-regulation in germinal centers ofthespleen.Subsequently,theactivated retroviruses disappeared inaPrP-dependentmanner.
Our results reveal the regular involvement of endogenous retroviruses in murine immune responses and provide evidence for an
essential function of PrP in the control of the retroviral activity. The interaction between PrP and ubiquitous endogenous
retroviruses may allow new interpretations of TSE pathophysiology and explain the evolutionary conservation of PrP.
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INTRODUCTION
The prion protein (PrP) is essential for the susceptibility to
transmissible spongiform encephalopathies (TSE) such as Creutz-
feldt-Jacob disease (CJD) in humans, bovine spongiform enceph-
alopathy (BSE) in cattle, scrapie in sheep and goats, and chronic
wasting disease (CWD) in deer and elk [1]. In the absence of PrP,
TSE symptoms do not develop [2], and the accumulation of
misfolded PrP in diseased tissue is a hallmark of TSE. According to
the widely accepted protein-only hypothesis, misfolded PrP itself
constitutes the infectious agent [3]. Yet, this dogma awaits to be
proven and is challenged by strong evidence for the involvement of
non-PrP molecules as ‘‘partners in crime’’ [4]. A recent study
demonstrated that synthetic poly(A) RNA, added to purified native
hamster PrP, is a sufficient stoichiometric cofactor for in vitro
amplification of misfolded PrP [5].
Remarkably, hamsters inoculated with samples obtained by
these amplification experiments developed TSE. Rather un-
expectedly though, the disease occurred not only with samples
from amplification that had been initiated by a seed of misfolded
PrP originating from diseased hamster brain, but likewise with
samples from amplification that had started spontaneously, i.e. in
the absence of an initial TSE seed. Moreover, strain characteristics
of TSE caused with inoculum from seeded and spontaneous in vitro
amplification were undistinguishable, but they differed from TSE
caused with inoculum of misfolded PrP that was used to seed
amplification. Hence, TSE strain characteristics of the inoculum
generated by in vitro amplification seemed to be imprinted not by
a seed of misfolded PrP, as the protein-only hypothesis would
entail [3], but rather by the accessory poly(A) RNA. The putative
role of RNA in TSE is also supported by a related study reported
earlier [6], where the accessory component extractable from tissue
homogenate and sufficient for in vitro amplification of misfolded
PrP was recognized to be particular RNA. By other researchers,
RNA aptamers specifically interacting with native or misfolded
PrP were isolated by in vitro selection [7,8]. This indicates that in
complex mixtures, RNA species may compete for binding to PrP
conformers, which could be the basis for TSE strain formation and
interferences [9,10]. However, despite the evidence gained by
means of in vitro experiments for a cofactor role of RNA in TSE, no
TSE-specific RNA has ever been identified. Therefore, the roles of
PrP and possible cofactors in TSE have remained controversial.
The physiological function of PrP might be a key towards better
understanding TSE pathophysiology. Numerous reports from the
past two decades proposed various physiological roles of PrP in
processes as diverse as copper homeostasis, leukocyte differentiation
or neuritogenesis, indicating that PrP may serve more than one
purpose [4,11]. In addition, PrP is a broadly expressed and highly
conserved gene product [12,13], suggesting that susceptibility to
TSE,whichcouldbeconsideredanegativeselectioncriterionforthis
protein, isoutweighedbya vitalfunction of PrP.Though, this viewis
in harsh contrast with observations that PrP seems to be dispensable
for normal development and health of individual mammals [14,15].
Up to date, no concept has emerged that would reconcile the
conflicting aspects of this enigmatic protein.
We have recently described an up-regulation of PrP in the
germinal centers of mouse spleens following immune-stimulation
[16]. Although this regulation is suggestive of an immunological
role of PrP, no consequences of the increased PrP level could be
demonstrated. Here we report that PrP up-regulation occurs in
response to massive appearance of endogenous murine retro-
viruses in the germinal centers upon immune-stimulation. We
show that elevated PrP expression helps to reduce the retroviruses
to the level before their activation, whereas in the absence of PrP
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a key role of PrP in the control of activated endogenous
retroviruses. Our findings may resolve the aforementioned conflict
in the conception of PrP function and suggest a plausible candidate
for an RNA species possibly involved in TSE.
RESULTS
Co-localized massive appearance of endogenous
murine retroviruses and increased PrP expression in
immune-stimulated splenic FDC networks
Splenic PrP up-regulation was observed 8 days after infection of
naı ¨ve mice with vesicular stomatitis virus (VSV) or intravenous
administration of preformed immune complexes [16]. By
immunofluorescence staining, up-regulated PrP was detected in
the network of follicular dendritic cells (FDC), but its exact
localization with respect to FDC dendrites and adjacent
lymphocytes remained unknown. Therefore, we examined splenic
germinal centers of immune-stimulated mice by transmission
electron microscopy (TEM). Staining of ultrathin sections with PrP
specific antibodies yielded an immunogold labeling confined to
FDC dendrites (Figure S1). Surprisingly, dendrites of immune-
stimulated and PrP-expressing FDC were decorated with numer-
ous electron-dense, enveloped particles resembling type C retro-
viruses (Figure 1A). Their retroviral nature was assessed by
staining with a rat antibody specific for the envelope protein (Env)
of murine leukemia retroviruses (MLV), resulting in an immuno-
gold labeling on the outer face of the virus particles (Figure 1A
inset). In contrast to Env, no PrP presence was revealed in the viral
particles, despite morphological evidence for MLV budding from
the PrP-expressing FDC (Figure S1).
In fluorescence microscopy, three different antibodies specific
for MLV envelope glycoprotein and capsid protein p30, respec-
tively, labeled structures on spleen cryosections that co-localized to
FDC networks with strong PrP immunostaining (Figure S2).
Whereas MLV staining appeared granular, PrP staining seemed
continuous along the FDC dendrites (Figure 1B).
We used the p30-specific antibody for Western blot analysis of
spleen homogenates from naı ¨ve and VSV-infected C57BL/6 mice
to assess whether the observed MLV particles were associated with
the formation of mature p30 protein. In addition to the
characteristic band at 30 kDa observed after immune-stimulation,
the anti-p30 staining revealed precursor forms of p30 in all tested
C57BL/6 spleen samples (Figure 2A). To assure that the 30 kDa
band of p30 protein was representative for mature MLV, the
activity of reverse transcriptase (RT) in the spleen homogenates
was analyzed. The RT activities, as detected by product-enhanced
RT (PERT) assay, strictly correlated with the respective p30
signals at 30 kDa (Figure S3). This validated p30-specific
immunoblot analysis as a tool to estimate the abundance of
matured MLV in splenic tissue.
Additional Western blot analyses revealed that infection of
C57BL/6 mice with lymphocytic choriomeningitis virus (LCMV)
and administration of thioglycolate or lipopolysaccharide (LPS)
also activated endogenous retroviruses (Figure 2A). The broad
spectrum of effective immune-stimuli suggested that PrP up-
regulation and MLV appearance were consequences of activated
adaptive and innate mechanisms of resistance. This is consistent
with the fact that splenic PrP up-regulation is dependent on the
complement component C1q [16]. Similar to C57BL/6 mice,
DBA/2 and BALB/c mice showed augmented MLV activity
following immune-stimulation by VSV infection as assessed by p30
Western blot analysis and PERT assay (Figures 2B and 4A), and
responded with PrP up-regulation (Figure 2B). In contrast, 129/Sv
did not show increased retrovirus activity following VSV immune-
stimulation and also failed to up-regulate PrP expression
(Figure 2B, 2D, 3, and 4A).
Partial sequence identification of immune-
stimulated MLV
Since the most likely origin of the observed MLV particles is the
activation of proviral genes, 129/Sv might lack these particular
proviruses, in analogy to the reported paucity of AKR-like
proviruses in mouse 129 strains [17]. Clarification of this issue
was expected from the identification of MLV-specific proviral
genes involved in the observed appearance of MLV particles in
immune-stimulated mouse spleens. First, we analyzed total splenic
RNA using real-time RT-PCR with a primer-probe set of broad
specificity for MLV-related RNA sequences. All spleen samples
tested positive for MLV RNA, without significant differences
Figure 1. Microscopic revelation of numerous MLV particles in FDC
network with increased PrP expression after immune-stimulation of
a C57Bl/6 mouse with IC. (A) Ultrastructure of splenic FDC revealed by
TEM. Large panel displays plastic section 70 nm thin, showing
lymphocytes with dark round nuclei (L), and part of an FDC with
lobate nucleus (F) and labyrinthine extensions. Small dark spots (arrows)
on FDC extensions represent viral particles. Bar, 2.5 mm. Inset shows
cryosection 90 nm thin, depicting viral particles on FDC extension. Dot-
like gold particles represent immunostaining specific for MLV Env
protein. Bar, 0.5 mm. (B) Co-localized immunofluorescence staining of
PrP and MLV Env in splenic germinal center. Semithin (400 nm)
cryosection was double-stained with rabbit serum specific for PrP and
rat monoclonal antibody specific for MLV Env. Bar, 25 mm.
doi:10.1371/journal.pone.0001158.g001
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most likely reflected the general abundance of MLV-related RNA
species in mouse spleens, as indicated already by the notable RT
‘‘background’’ activity level of naı ¨ve spleen lysates (Figure 4A).
Therefore, we isolated MLV particles from immune-stimulated
spleen tissue by Env-specific immunoadsorption and subsequently
extracted the particle-associated MLV RNA (Figure S4). Com-
plementary DNA corresponding to the purified MLV RNA was
amplified and subcloned. From the subcloned PCR products two
sequences of 732 nucleotides each were identified. They are
homologous to published MLV-related sequences in the NCBI
GenBank, with accession number U63133 (nucleotide range
2058–2789) and X94150 (range 2061–2792), respectively. Because
these sequences seemed to represent immune-activated murine
endogenous retroviruses, we named them IMERV-1 (homologous
to U63133) and IMERV-2 (X94150). Their up-regulation upon
immune-stimulation was confirmed by real-time RT-PCR analysis
of total RNA isolated from C57Bl/6 spleens (Figure 4B). In-
terestingly, no RNA related to IMERV-1 or IMERV-2 was
detected in naı ¨ve or immune-stimulated 129/Sv spleens
(Figure 4B). Genomic IMERV-1 and IMERV-2 sequences were
detected in C57Bl/6, DBA/2 and BALB/c mice, but were absent
in 129/Sv mice (Table 1). These results corroborated the special
status of 129/Sv mice with regard to their retroviral repertoire.
PrP up-regulation in response to high MLV activity
The IMERV deficiency and the missing splenic PrP up-regulation
of 129/Sv mice pointed to a possible dependence of PrP up-
regulation on MLV activity. We first tested this hypothesis in a cell
culture model of 3T3 fibroblasts infected in vitro with MLV.
Western blot analysis of cell lysates showed that MLV-propagating
cells expressed significantly more PrP than non-infected control
3T3 fibroblasts (Figure S5). Thus, the presence or activity of MLV
is associated with increased PrP expression. Importantly, this PrP
increase was not correlated with an increase of PrP-related RNA
(Table 1), suggesting that a mechanism independent of transcrip-
tion was involved. Correspondingly, in mice splenic PrP was up-
regulated posttranscriptionally after immune-stimulation [16].
This indicated that PrP up-regulation occurred more specifically
than just by broad gene activation in response to viral burden.
We examined splenic PrP expression and the presence of MLV
p30 over 14 days following immune-stimulation of C57Bl/6 mice
by VSV infection (Figure 2C). Retroviral p30 increased at day 5
post-infection, peaked around day 8 and decreased again by day
14. Increased PrP expression was detected by day 8 and persisted
beyond day 14. Thus, the kinetics was in line with the assumption
that splenic PrP up-regulation occurred in response to IMERV,
but also that increased PrP expression might be linked to IMERV
regression.
Retrovirus regression in response to increased PrP
expression
If there was an inhibitory effect of up-regulated PrP on IMERV,
then PrP-deficient mice should show sustained IMERV activity.
To address this subject, Prnp knockout mice were assessed for the
presence of IMERV and their clearance kinetics.
One line of Prnp
0/0 mice [14], which were generated on a mixed
129/Sv-C57BL/6 background, did not show IMERV activity
(data not shown) or proviral DNA (Table 1) and was therefore not
further evaluated. In contrast, Prnp
2/2 Nagasaki mice were
established on a pure C57BL/6 background [18] and found to be
IMERV-competent. They were compared with C57Bl/6 wild-
type mice (PrP- and IMERV-competent) and 129/Sv wild-type
mice (PrP-competent, IMERV-deficient) on day 8 and day 30 after
VSV infection (Figure 2D and 3). In 129/Sv spleens, no MLV p30
was detected at any time point and PrP expression remained low.
C57BL/6 wild-type spleens revealed high MLV p30 and PrP
Figure 2. Immunoblots showing increase of PrP and mature MLV p30 in spleens of immune-stimulated mice. (A) Comparison of PrP and mature
p30 abundance following various immune-stimuli. C57Bl/6 mice were infected with VSV or LCMV, or treated with thioglycolate (TG) or
lipopolysaccharide (LPS). Eight days after immune-stimulation spleen homogenates were analyzed by Western blot for PrP (upper panels) and p30
(lower panels). Representative blots are shown. Protein bands revealing mature p30 protein are boxed. (B) Capacity of various inbred mouse strains
to respond to VSV infection with increased abundance of PrP and p30. Mice of the strains DBA/2, BALB/c and 129/Sv were infected with VSV. Splenic
PrP and MLV p30 were analysed on day 8 after infection. Representative blots are shown. (C) Kinetic of PrP and p30 abundance following VSV
infection. Spleens of C57BL/6 mice were analyzed on day 0, 3, 5, 8 and 14, respectively, after infection. In the presented Western blots homogenates
of three spleens per time point group were pooled for analysis, in order to obtain averaged results. (D) Different kinetics of PrP and p30 abundance in
129/Sv, C57BL/6 and Prnp
2/2 (Nagasaki) mice. Spleens were analyzed on day 0, 8 and 30, respectively, after infection. Per experimental group
homogenates of three spleens were pooled.
doi:10.1371/journal.pone.0001158.g002
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PrP expression was still high, MLV p30 expression had nearly
vanished. In contrast, in C57BL/6 mice lacking PrP (Prnp
2/2
Nagasaki) MLV p30 was found enhanced on day 8 and stayed
high at least until day 30. Hence, these results support our
hypothesis that PrP up-regulation negatively controls the splenic
presence of IMERV. An uncertainty about the correct in-
terpretation, however, was caused by the known particularity of
Prnp
2/2 Nagasaki mice to ectopically express Doppel protein
(Dpl), a PrP paralogue, in the brain [19]. Conceivably, Dpl may as
well be ectopically expressed in the splenic FDC network, and if
so, the persistence of IMERV in Prnp
2/2 Nagasaki mice might not
be the result of PrP absence but of Dpl presence. Immunohisto-
chemistry indeed revealed that Dpl was expressed in the splenic
FDC network of Prnp
2/2 Nagasaki mice. In the Prnp
+/2 F1
generation of a crossing of C57Bl/6 wild-type and Prnp
2/2
Nagasaki mice, both PrP and Dpl were localized in the FDC
network (Figure S6). This co-localization permitted us to show that
PrP expression in Prnp
+/2 F1 mice restored the phenotype of
IMERV regression (Figure 4C) irrespective of a putative role of
splenic Dpl in IMERV activity.
Figure 3. Immunohistochemistry illustrating the interdependence of
PrP and IMERV in the splenic FDC network. Frozen spleen sections
representing 129/Sv wild-type, C57Bl/6 wild-type and Prnp
2/2 (Naga-
saki) mice on C57Bl/6 background, infected with VSV for 0, 8 and
30 days. Sections were double-stained with rabbit serum specific for
PrP (upper row) and goat serum specific for MLV p30 (lower row). Bar,
100 mm.
doi:10.1371/journal.pone.0001158.g003
Figure 4. Quantification of splenic IMERV activity. Open plot symbols
represent naı ¨ve, filled symbols VSV-infected C57Bl/6 (%,&), BALB/c
(n,m), DBA/2 (,,.) or 129/Sv (#,$) mice. Short horizontal lines
indicate average values of respective experimental categories. (A) RT
activity in spleen homogenates on day 8 after VSV infection, as
revealed by PERT assay. (B) Relative abundance of RNA with IMERV-1
and IMERV-2 specific sequences on day 8 after VSV infection, as
assessed by real-time RT-PCR on total splenic RNA. (C) Relative
abundance of mature MLV p30 in spleen homogenates on day 30
after VSV infection, as determined by densitometric quantification of
immunoblots. Samples were obtained from C57Bl/6 wild-type mice (+/
+), Prnp
2/2 (Nagasaki) mice (2/2) and F1 offsprings of a crossing of the
former two lines (+/2).
doi:10.1371/journal.pone.0001158.g004
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The present study has revealed that PrP up-regulation occurring in
the mouse spleen after immune-stimulation coincides and co-
localizes with the transient appearance of endogenous MLV
(IMERV). Because PrP up-regulation did not occur in mice that
lack the respective IMERV, and in turn, IMERV persisted in the
spleen of mice without PrP expression, we conclude that splenic
PrP expression plays a crucial role in the negative feedback control
of immune-activated endogenous MLV.
Whether PrP expression and retroviral activity are similarly
interconnected in non-splenic tissues and other mammalian
species remains to be determined, yet, support for such an
assumption is provided by cell culture experiments. Over-
expression of PrP counteracted the formation of endogenous
MLV in N2a neuroblastoma cells (data not shown) and repressed
HIV-1 in an infected human cell line [20]. These findings also
indicate that the antiretroviral function of PrP might rely on cell-
autonomous mechanisms. In the case of HIV-1 repression PrP was
reported to interfere with the synthesis of distinct viral proteins on
the level of translation [20], implying an interaction with retroviral
RNA. In support of such an interaction, functional binding of PrP
to retroviral RNA was demonstrated in a cell-free system [21], and
PrP was found to be present not only in cell membranes but also in
the cytosol [22]. Although PrP binding to retroviral RNA in
mammalian cells waits to be confirmed, it is consistent with the
concept of PrP and RNA partnering in TSE as summarised in the
Introduction. We propose that PrP binding to retrovirus-related
RNA is crucial for the antiretroviral effect of PrP expression as well
as the pathophysiology of TSE. The latter may explain the
interactions observed between TSE and (endogenous) retroviruses
in murine in vitro and in vivo models [23–25]. The involvement of
retrovirus-related RNA in TSE might also account for the
activation pattern of microglia that was found to be reminiscent
of an inflammatory response to latent or persistent viruses rather
than to amyloidogenic proteins (including abnormal PrP) [26].
Besides the combined evidence for an involvement of retrovirus-
related RNA in TSE, it is worth mentioning that in mammals this
RNA species occurs ubiquitously, on occasion abundantly, and in
various sizes (down to the range of small interfering RNA).
Omnipresence or small size could be reasons why no TSE-specific
RNA was identified so far. In addition, RNA species can adopt
various conformations, and therefore, tissue preparations contain-
ing (enriched) TSE infectivity may fail to show TSE-specific
ribonucleotide sequences because TSE specificity is imprinted in
the secondary structure. According to our model, in which
interacting PrP and RNA both can assume TSE-related
conformations, principally either binding partner might be able
to initiate per se propagation of the TSE agent. For the
maintenance of propagation and strain characteristics, however,
we assume the interaction of both components, PrP and RNA, to
be required (in accordance with the results of Deleault et al. [5]).
The massive appearance of IMERV in the FDC network of the
mouse spleen is a remarkable finding by itself. Because IMERV
activity occurred in response to various immune-stimuli and in
several inbred mouse strains, it may be a common trait with
physiological functions. Evidence for a connection between
endogenous C-type viruses and the humoral immune response of
mice was reported already three decades ago [27]. Since then,
diverse immunological roles have been discussed for endogenous
retroviruses [28] and we may speculate that IMERV activity
likewise can provide antiviral resistance or modulate immune
responses. The absence of genomic IMERV sequences and
IMERV activity, as reported here for 129/Sv mice, might
therefore be associated with immunological aberrations. Indeed,
mice of the 129 strain show deficits in macrophage recruitment as
well as NK and B cell activation [29–31]. The causes of these
deficiencies have remained elusive, however, the macrophage
impairment was reported to be a polygenic trait [29], which might
be consistent with the absence of IMERV-related genes.
Regarding the putative immunological impact of IMERV,
control of IMERV-like activity may be important, all the more
since retroviral activity in general increases the risks of insertional
modifications of the genome or the emergence of new retroviral
pathogens [32]. The PrP function suggested here might well
extend to the control of further retroviral elements in addition to
IMERV, as indicated by the potential of PrP revealed in in vitro
studies [20,21,33]. Still, for individual animals the restriction of
retroviral activity by PrP might be dispensable, like any proposed
role of PrP, as implicated for instance by the viability of inbred
PrP-deficient laboratory mice. However, it might be vital at the
species level to limit risks posed by the activity of endogenous
retroviral elements.
In summary, our experiments have revealed, by correlation,
a crucial role of PrP expression in the limitation of a common, but
previously unrecognized, phenomenon in the mouse spleen,
namely the massive activity of endogenous retroviruses in germinal
centers after various immune-stimulations. The biological signif-
icance of transient retroviral activity in the spleen and anti-
Table 1. Quantification of PrP-related RNA, MLV-related
RNA (broad specificity), and IMERV-related DNA by real-time
(RT-)PCR.
......................................................................
Type of quantified
nucleic acid
Sampled mouse cells or spleen
tissue
Relative
abundance
PrP RNA 3T3 cells, non-infected 100%
3T3 cells, MLV-infected 93%
MLV RNA (broad) 3T3 cells, non-infected 100%
3T3 cells, MLV-infected 11’143%
N2a cells, non-infected 606%
C57BL/6, naı ¨ve 1’300%
C57BL/6, VSV-infected (8d) 1’213%
129/Sv, naı ¨ve 985%
129/Sv, VSV-infected (8d) 1’056%
IMERV-1 DNA C57BL/6 100%
DBA/2 115%
BALB/c 123%
129/Sv 0%
Prnp
0/0 (Zu ¨rich) 0%
F1 (Prnp
0/0 (Zu ¨rich)6C57BL/6) 50%
Prnp
2/2 (Nagasaki) 100%
IMERV-2 DNA C57BL/6 100%
DBA/2 115%
BALB/c 100%
129/Sv 0%
Prnp
0/0 (Zu ¨rich) 0%
F1 (Prnp
0/0 (Zu ¨rich)6C57BL/6) 47%
Prnp
2/2 (Nagasaki) 107%
Comparison of samples was made within sections defined by type of quantified
nucleic acid. For the top sample of each section RNA or DNA abundance was
arbitrarily set to 100%.
doi:10.1371/journal.pone.0001158.t001
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1158retroviral PrP function remains to be established. Yet, our findings
offer an intriguing new viewpoint from which the conceptual
conflicts thus far associated with PrP function and TSE
pathophysiology may be resolved.
MATERIALS AND METHODS
Mice
All mice were bred and maintained under SPF-conditions and
experiments performed in accordance with institutional and Swiss-
national guidelines. Wild-type C57BL/6 and 129/Sv mice were
purchased from the Institute of Laboratory Animals (Vetsuisse
Faculty, University of Zu ¨rich, Switzerland). DBA/2 and BALB/c
mice were obtained from Harlan Netherlands (Horst, Nether-
lands). Prnp
o/o (Zu ¨rich line, mixed C57BL/6x129/Sv background)
and Prnp
2/2 (Nagasaki line, C57BL/6) mice were kindly provided
by Adriano Aguzzi (Institute of Neuropathology, University of
Zu ¨rich, Switzerland).
Virus infection of mice
VSV-Indiana (VSV-IND) growth and infection were performed as
described before [16]. LCMV strain WE was originally obtained
from Fritz Lehmann-Grube (Heinrich Pette Institute, University of
Hamburg, Germany) and propagated on L929 and/or MC57
cells. Mice were infected with 2610
2 plaque forming units (PFU)
LCMV-WE injected intravenously as indicated. To avoid
immune-pathological destruction of splenic microarchitecture,
mice were depleted of CD8+ T cells prior to LCMV infection
by monoclonal antibody (YTS 169.4) as previously described.
Non-viral immune-stimulation
Mice were immunized intravenously with IC, as previously
described [16], or with LPS (15 mg intravenously/mouse; DIFCO
Laboratories, Detroit, USA). 1.5ml thioglycolate 3% (DIFCO
0256-17) was administered intraperitoneally. Because VSV in-
fection was the most efficient immune-stimulus for C57Bl/6 mice,
it was chosen for comparative experiments comprising other
mouse strains. Successful immune-stimulation was associated with
significantly increased spleen net weight, in comparison to naı ¨ve
controls of the same experimental series, and was readily achieved
with C57Bl/6, DBA/2, 129/Sv and the Prnp knockout mice.
However, BALB/c mice exhibited increased spleen weight in only
one out of two experimental series. BALB/c data of the successful
series are shown.
Electron microscopy
From mouse spleens that were perfusion-fixed with 4% formal-
dehyde and 0.1% glutaraldehyde small pieces of white pulp were
dissected. For plastic embedding, white pulp samples were post-
fixed in 1% glutaraldehyde over-night and subjected to standard
procedures of osmification, dehydration and Epon embedding.
Ultrathin plastic sections were picked up on copper grids and
contrasted with uranyl acetate and lead citrate. For immunogold-
TEM white pulp samples were immersed for 48 h in 2 M sucrose
containing 15% polyvinyl pyrrolidone (10 kDa; Sigma), mounted
on aluminum pins and frozen and stored in liquid nitrogen.
Ultrathin cryosections were prepared according to Tokuyasu [34]
and picked up on nickel grids. Incubation of sections was
performed by floating the grids on droplets of the respective
solution. Immunolabelling was carried out with specific antibodies
diluted in conditioning buffer (PBS containing 0.5% milk powder
and 0.02% Tween). PrP-specific immunostaining was achieved
with rabbit serum XN [16] at a dilution of 1:200. MLV Env-
specific immunostaining employed rat monoclonal antibody
83A25 [35] at 1:2 and subsequent rabbit-anti rat (Jackson
ImmunoResearch Laboratories Inc., West Grove, PA) at 1:300.
Antibody binding was indirectly gold-labeled by incubation with
8- and 12-nm gold-complexed protein A, respectively. Immuno-
labelled sections were embedded and stained with methylcellulose
and uranyl acetate according to Tokuyasu [34]. Micrographs were
taken on a Zeiss EM 910.
Immunohistochemistry
Semithin sections of 400 nm were prepared from sucrose-
infiltrated aldehyde-fixed spleen tissue as for ultrathin cryotomy.
Preparation of cryostat sections from non-fixed spleen samples and
immunostaining were carried out as previously described [16].
Primary antibodies were the following: PrP-specific rabbit
antiserum XN at 1:600, MLV Env-specific rat antibody 83A25
at 1:3, MLV gp71-specific goat serum (kindly provided by Roland
Friedrich, Microbiology and Virology, University of Giessen,
Germany) at 1:3000, MLV p30-specific goat serum (kindly
provided by Hans Lutz, Vetsuisse Faculty, University of Zu ¨rich,
Switzerland) at 1:1500, and Dpl-specific affinity-purified goat
antibody Dpl (G-20) (Santa Cruz Biotechnology Inc., Santa Cruz,
CA) at 1:50.
Western blot and PERT analysis
For Western blot analysis, spleen tissue and cell culture sample
preparations, electrophoresis and immunoblot detection were
performed as decribed previously [16]. Employed primary
antibodies were PrP-specific polyclonal rabbit antibody 1B3 [16]
at 1:5000, and MLV p30-specific antibody at 1:10’000. For
determination of splenic reverse transcriptase activity, 10%
homogenates of spleen samples prepared for Western blot analysis
were diluted 1:1000 and subjected to PERT assays as described
elsewhere [36] (making use of a modification for real-time
detection).
Cell culture experiments
Mouse fibroblasts of the 3T3-Swiss albino cell line were cultured
as described previously [16]. For infection with Moloney type
MLV culture medium was complemented 1:2 with 0.45mm-
filtered virus-containing supernatant with a titer .10
7 pfu/ml
(viral stock kindly provided by Tatiana Afanasieva, Institute of
Neuropathology, University of Zu ¨rich, Switzerland) and 8 mg/ml
polybrene (Sigma). Medium was exchanged the next morning.
Mock-infected and MLV-infected fibroblast cultures were pas-
saged after 3 days and harvested on day 5 for Western blot
analysis.
Specific MLV particle isolation
An approximate amount of 4610
7 paramagnetic beads (Dyna-
beads M450) with covalently linked sheep anti-rat IgG (Dynal
Biotech, Oslo, Norway) was washed, resuspended in 800 ml PBS/
0.1%BSA and added to 1 ml of MLV Env-specific supernatant
83A25 for incubation over-night at 4uC to obtain MLV-specific
beads. A 20% homogenate of immune-stimulated mouse spleen
tissue was prepared in 10 mMTris-HCl pH 7.5 supplemented with
1 mM EDTA, 100 mM NaCl and 5% sucrose. The homogenate
was centrifuged for 30 min at 10’000g and 4uC, and 0.5 ml of the
supernatant was added to washed MLV-specific beads (or, as
a negativ control, to an equal amount of original rat IgG-specific
beads) and incubated for 2 h at ambient temperature. After
incubation beads were collected, washed and processed either for
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ination, or for RNA isolation.
RNA and DNA extraction
Total RNA from paramagnetic bead fractions, spleens, or cells was
obtained by direct lysis of the samples in TRI reagent (MRC Inc.)
and further processing according to the manufacturers protocol.
Putative traces of contaminating DNA were removed with DNA-
free
TM Kit (Ambion Inc.).
DNA was extracted from mouse tail, spleen or brain by
decomposing tissue in tail lysis solution over-night at 55uC. After
brief centrifugation of the lysate, DNA was precipitated from the
supernatant with isopropanol. Precipitate was washed with 70%
ethanol, air-dried and reconstituted in 50 mM Tris-HCl pH 8.
Reverse transcription and PCR amplification
Reverse transcription on RNA extracted from paramagnetic bead
fractions was performed using the SuperScript
TM First-strand
Synthesis System for RT-PCR (Invitrogen) with random hexame-
ric primers according to the manufacturers instructions. Sub-
sequent PCR amplification employed the following primers:
forward 59-ataacccagggacctaatgagtc-39 for broad Friend-MLV
genome-related specificity, forward 59-ataacacaagggcccaatga-39
for broad Moloney-MLV genome-related specificity, and reverse
59-cttccacccgcttgttga-39 for both of them.
Cloning and sequencing
PCR products were isolated and purified with the QIAquick Gel
Extraction Kit (Qiagen). Cloning was performed by use of the
pGEMH-T Easy Vector System kit (Promega) and competent E.
coli JM109 cells (Promega). Plasmids were purified with the
Plasmid Midi Kit (Qiagen) and the inserts sequenced on an ABI
377 sequencer using Big Dye terminator chemistry (Applied
Biosystems) and custom primers.
RNA and DNA quantification by real-time PCR
Real-time RT-PCR analysis of RNA was performed as described
previously for GAPDH (internal standard) and PrP-related RNA
[16]. The primer-probe set with broad specificty for MLV was:
forward 59-aagcgggtggaagacatcc-39, reverse 59-agcccgctcaa-
gaggttgt-39, probe FAM-59-ccccaccgtgcccaaccct-39-TAMRA.
The primer-probe set specific for IMERV-1 was: forward 59-
cactttgagggatcaggagcc-39, reverse 59-cttctaggtttagggtcaacacctgt-39,
probe FAM-59-aggttgtgggaccaaaaggacagcc-39-TAMRA. For IM-
ERV-2-related RNA, the set was: forward 59-cacttcgagggatcgg-
gagct-39, reverse 59-cctctatgccaagggtcaacacctgc-39, same probe as
for IMERV-1.
The procedure for real-time PCR analysis of DNA was identical
to the one for RNA analysis except that the template nucleic acid
was 5 ng DNA per reaction and the reverse transcription step was
omitted.
SUPPORTING INFORMATION
Figure S1 TEM of ultrathin cryosections through the germinal
center of a mouse spleen showing an FDC (F) with its labyrinthine
extensions between lymphocytes (L). The wild-type mouse of the
C57Bl/6 strain was immune-stimulated 8 days before by in-
travenous IC. PrP-specific immunogold labelling (small black dots)
is restricted to the FDC extensions. Retrovirus-like particles can
also be discerned, with the morphology of mature (arrows) and
immature budding virus (arrowhead). Bar, 500 nm.
Found at: doi:10.1371/journal.pone.0001158.s001 (1.40 MB TIF)
Figure S2 Immunofluorescence staining obtained with antibo-
dies directed against MLV Env, gp71 and p30 on consecutive
cryosections of spleens of C57Bl/6 mice on day 8 after VSV
infection. On each section double-staining revealed the MLV
protein in conjunction with PrP. Bar, 100 mm.
Found at: doi:10.1371/journal.pone.0001158.s002 (0.09 MB
PDF)
Figure S3 Correspondence of mature MLV p30 abundance and
reverse transcriptase (RT) activity in mouse spleens. Homogenates
from naı ¨ve (first from the left) and immune-stimulated C57BL/6
spleens were analysed by Western blot for the p30 protein band at
the 30 kDa position (immunoblots at bottom) and by PERT assay
for RT activity.
Found at: doi:10.1371/journal.pone.0001158.s003 (0.05 MB
PDF)
Figure S4 Isolation and amplification of immune-activated
MLV-related RNA sequences. (A) Immunoabsorptive isolation of
viral particles. Paramagnetic beads were incubated in homogenate
of immune-stimulated C57BL/6 spleens, washed and then
processed for RNA isolation or for visual control by TEM.
Electron micrographs of ultrathin plastic sections show beads
without specificity for MLV (left panel), and the surface of an Env-
specific bead with bound viral particles (right panel). Bar, 1 mm. (B)
MLV-specific RT-PCR products obtained with RNA preparations
from immunoabsorptive bead samples. Reverse transcription and
amplification of RNA from cultivated Moloney MLV (positive
control, lane 1), from non-specific bead samples (lanes 2 and 4)
and from Env-specific bead samples (lanes 3 and 5) were
performed with primer pairs specific for Moloney type (lanes 1–
3) and for Friend type MLV sequence (lanes 4 and 5), respectively.
Visible bands (lanes 1 and 5) represent products of the expected
size of 1.3 kilobases. Marker, lane 6.
Found at: doi:10.1371/journal.pone.0001158.s004 (0.14 MB
PDF)
Figure S5 Increased PrP and p30 expression by 3T3 fibroblasts
following infection with Moloney MLV. Retrovirus infection was
established within 5 days with cell passage in fresh medium. Per
experimental group, i.e. control cells (2 MLV) and infected cells
(+MLV), lysates of three cell cultures were pooled for analysis in
the presented Western blots, in order to obtain averaged results.
Found at: doi:10.1371/journal.pone.0001158.s005 (0.03 MB
PDF)
Figure S6 Dpl and PrP expression in splenic FDC networks of
Prnp2/2 (Nagasaki), C57Bl/6 wild-type Prnp+/+ mouse and F1
offspring of Prnp2/2 (Nagasaki)/C57Bl/6 wild-type crossing
(Prnp+/2), on day 8 after VSV infection. Dpl and PrP were
revealed by immunofluorescence double-staining. Bar, 100 mm.
Found at: doi:10.1371/journal.pone.0001158.s006 (0.09 MB
PDF)
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